Citronellyl formate is an ester synthesized by reacting citronellol with formic acid. It is a colorless liquid with a sweet, floral, and citrusy odor. Citronellyl formate is a common ingredient in perfumes, cosmetics, and soaps. It is also used as a flavoring agent in food and beverages. Research on citronellyl formate focuses on its potential applications in insect repellents and as an antimicrobial agent. Studies have shown that citronellyl formate exhibits insecticidal and anti-fungal activity, suggesting its potential for use in pest control and as a natural preservative. The compound is particularly interesting due to its pleasant odor and its low toxicity to mammals, making it a promising alternative to synthetic pesticides. Further research is ongoing to explore its full potential and optimize its application in different areas.'
citronellyl formate: a volatile oil from Pelargonium graveoleus [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Pelargonium | genus | A plant genus of the family GERANIACEAE. The common name of geranium is also used for the GERANIUM genus.[MeSH] | Geraniaceae | A plant family of the order Geraniales, subclass Rosidae, class Magnoliopsida.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 7778 |
| CHEMBL ID | 3184928 |
| CHEBI ID | 31406 |
| SCHEMBL ID | 416782 |
| MeSH ID | M0172770 |
| Synonym |
|---|
| 6-octen-1-ol,3,7-dimethyl-, 1-formate |
| 3,7-dimethyl-6-octen-1-yl formate |
| formic acid, citronellyl ester |
| nsc46117 |
| wln: vho2y1&3uy1&1 |
| 2,6-dimethyl-2-octen-8-yl formate |
| formic acid,7-dimethyl-6-octen-1-yl ester |
| 6-octen-1-ol,7-dimethyl-, formate |
| nsc-46117 |
| brn 1723215 |
| formic acid, 3,7-dimethyl-6-octen-1-yl ester |
| citronellyl methanoate |
| einecs 300-075-2 |
| ai3-24239 |
| 3,7-dimethyl-6-octen-1-yl methanoate |
| einecs 203-338-9 |
| nsc 46117 |
| citronellol formate |
| (1)-3,7-dimethyloct-6-enyl formate |
| fema no. 2314 |
| 6-octen-1-ol, 3,7-dimethyl-, formate |
| citronellyl formate |
| 105-85-1 |
| citronellyl formate, fcc |
| LMPR0102010014 |
| 3,7-dimethyloct-6-enyl formate |
| 3,7-dimethyloct-6-en-1-yl formate |
| 93919-93-8 |
| NCGC00248262-01 |
| dtxcid9024772 |
| NCGC00254933-01 |
| tox21_301031 |
| cas-105-85-1 |
| dtxsid1044772 , |
| (-)-3,7-dimethyloct-6-enyl formate |
| 93919-91-6 |
| (+)-3,7-dimethyloct-6-enyl formate |
| einecs 300-078-9 |
| einecs 300-076-8 |
| AKOS016009786 |
| 7b1my2brdk , |
| 6-octen-1-ol, 3,7-dimethyl-, 1-formate |
| 2-02-00-00032 (beilstein handbook reference) |
| unii-7b1my2brdk |
| FT-0623969 |
| SCHEMBL416782 |
| citronellyl formate [fhfi] |
| citronellyl formate [fcc] |
| citronellyl formate, (+/-)- |
| (+/-)-citronellyl formate |
| DZNVIZQPWLDQHI-UHFFFAOYSA-N |
| 3,7-dimethyl-6-octenyl formate # |
| citronellol formate (6ci) |
| CHEBI:31406 , |
| W-109390 |
| CHEMBL3184928 |
| AS-62928 |
| 2, 6-dimethyl-2-octen-8-yl formate |
| fema 2314 |
| citronelyl formate |
| Q27114304 |
| CS-0186751 |
| 6-octen-1-ol,3,7-dimethyl-,1-formate |
| F88176 |
| Class | Description |
|---|---|
| carboxylic ester | An ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 34.3762 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| AR protein | Homo sapiens (human) | Potency | 0.3696 | 0.0002 | 21.2231 | 8,912.5098 | AID743042; AID743054 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 68.5896 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 17.4891 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 48.9662 | 0.0002 | 29.3054 | 16,493.5996 | AID743069 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 61.6448 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 54.4827 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 61.6448 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 24.3365 | 0.0003 | 23.4451 | 159.6830 | AID743066 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 58.2929 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 43.2771 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 54.4827 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 61.1306 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 61.1306 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||